Top-line data from a trial testing an antibody cocktail in non-hospitalized people with the novel coronavirus show a reduction in the risk of hospitalization or death by 70%.
The Phase III REGN-COV 2067 study met its primary endpoint, comparing treatment with casirivimab and imdevimab with placebo.
The trial also met all key secondary endpoints, including the ability to reduce symptom duration from 14 to 10 days.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze